Daxor Corporation Receivables Turnover Ratio (DXR), from the fourth quarter 2011 to the fourth quarter 2010 current and historic results, rankings and more - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Daxor Corporation  (DXR)
 

Daxor Accounts Receivables Turnover Ratio from the fourth quarter 2011 to the fourth quarter 2010

Quarterly Results, Trends, Rankings, Statistics


Daxor Corporation's ability to collect accounts receivable sequentially worsen to 5.9, indicating more challenging environment then in the third quarter 2011, but still, it is a far cry from any concerns. Daxor's Accounts Receivable average collection period in the Dec 31 2011 quarter, has increased to 62 days, from 34 days, in the Sep 30 2011 quarter.

If we take a look into Healthcare sector Daxor Corporation achieved the highest receivable turnover ratio. While receivables turnover ratio remained unchanged relative to the previous period at no. .

What is Receivable Turnover Ratio?
What is Daxor Corporation Selling?


What is Receivable Turnover Ratio?




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

DXR Receivables Turnover Ratio (Dec 31 2011)
IV. Quarter		 (Sep 30 2011)
III. Quarter		 (Jun 30 2011)
II. Quarter		 (Sep 30 2010)
III. Quarter		 (Jun 30 2010)
II. Quarter
Y / Y Receivable Change - - - - -
Y / Y Revenue Change - - - - -
Receivable Turnover Ratio (TTM) 5.9 10.82 12.67 18.38 -
DXR's Total Ranking # # # # #
Accounts Receivable average collection period days 62 34 29 20 -
Seq. Receivable Change 15.87 % -2.02 % 8.22 % - -
Seq. Revenue Change - -4.8 % -21 % 23.08 % -


Receivable Turnover Company Ranking
Within: No.
Medical Equipment & Supplies Industry #
Healthcare Sector #
Overall Market #

Receivable Turnover Ratio Statistics
High Average Low
0 0 0
 





DXR Company Profile • Back to DXR Efficiency Comparisons • Compare DXR Receivables Turnover Ratio to its Competitors

Financial Statements
Daxor's Accounts Receivable $ 0 Millions Visit DXR's Balance sheet
Daxor's Sales TTM $ 1 Millions Visit DXR's Income Statement
Sources of DXR's Revenues Visit DXR's Sales by Geography

Other Accounts Receivable Turnover Ratios
Medical Equipment & Supplies Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
DXR's Receivable Turnover Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
DXR's Growth Rates DXR's Roa DXR's Inventory Turnover Ratio DXR's Dividend Comparisons
DXR's Profitability Ratios DXR's Roi DXR's Asset Turnover Ratio DXR's Dividend Growth
DXR's Valuation Ratios DXR's Roe DXR's Financial Strength Ratios DXR's Dividend Payout Ratio



Companies with similar Receivables Turnover Ratio for the quarter ending Dec 31 2011, within Healthcare Sector Receivable Turnover Ratio Revenues for 12 Months ending Dec 31 2011 Receivable at quarter ending Dec 31 2011
Incyte Corporation  13.58 $ 94.455  Millions$ 6.958  Millions
Chemed Corporation  13.50 $ 1,355.970  Millions$ 100.460  Millions
Acorda Therapeutics Inc   12.90 $ 292.237  Millions$ 22.662  Millions
Dyne Therapeutics Inc   11.87 $ 1,585.000  Millions$ 133.500  Millions
Immucell Corporation  11.82 $ 9.037  Millions$ 0.765  Millions
Dendreon Corp  11.80 $ 341.613  Millions$ 28.956  Millions
Bio techne Corp  10.86 $ 286.586  Millions$ 26.390  Millions
Amag Pharmaceuticals inc   10.07 $ 61.249  Millions$ 6.081  Millions
Nektar Therapeutics  10.04 $ 71.480  Millions$ 7.118  Millions
Luminex Corporation  9.97 $ 184.339  Millions$ 18.498  Millions
Jazz Pharmaceuticals Plc  9.65 $ 272.277  Millions$ 28.221  Millions
Vaso Corporation  9.58 $ 35.374  Millions$ 3.692  Millions
United Therapeutics Corporation  9.17 $ 743.183  Millions$ 81.003  Millions
Henry Schein Inc   9.05 $ 8,530.242  Millions$ 942.333  Millions
Merit Medical Systems Inc  8.96 $ 359.449  Millions$ 40.095  Millions
Myriad Genetics Inc   8.82 $ 417.483  Millions$ 47.332  Millions
Idexx Laboratories Inc  8.66 $ 1,218.689  Millions$ 140.766  Millions
Option Care Health Inc   8.61 $ 1,818.026  Millions$ 211.073  Millions
Masimo Corp  8.29 $ 435.936  Millions$ 52.566  Millions
Quest Diagnostics Inc  8.25 $ 7,479.428  Millions$ 907.115  Millions
Hologic Inc  8.05 $ 1,829.489  Millions$ 227.241  Millions
Patterson Companies Inc   8.04 $ 3,483.146  Millions$ 433.463  Millions
Biogen Inc   8.01 $ 5,048.623  Millions$ 630.056  Millions
Insulet Corporation  7.84 $ 152.255  Millions$ 19.415  Millions
Labcorp Holdings Inc   7.78 $ 5,542.300  Millions$ 712.650  Millions
Icu Medical Inc  7.73 $ 302.195  Millions$ 39.114  Millions
Vertex Pharmaceuticals Inc  7.73 $ 1,410.626  Millions$ 182.602  Millions
Tenet Healthcare Corp  7.72 $ 9,448.000  Millions$ 1,223.750  Millions
Agilent Technologies inc   7.67 $ 6,731.000  Millions$ 877.250  Millions
Allergan plc  7.59 $ 5,419.100  Millions$ 714.325  Millions

Date modified: 2026-09-08T17:29:55+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.